10-Deacetyl-7-xylosyl paclitaxel - CAS 90332-63-1
Catalog number:
90332-63-1
Category:
Inhibitor
Not Intended for Therapeutic Use. For research use only.
Molecular Formula:
C50H57NO17
Molecular Weight:
943.98
COA:
Inquire
Targets:
ADCs Cytotoxin
Description:
10-Deacetyl-7-xylosyl paclitaxel is a Paclitaxel derivative with improved pharmacological features and higher water solubility. It induced mitotic cell cycle arrest and apoptosis as measured by flow cytometry, DNA laddering, and transmission electron microscopy. Moreover, it had no effect on the expression of CD95 and NF-kappaB proteins, indicating that apoptosis was induced through the mitochondrial-dependent pathway in PC-3 cells.
Publictions citing BOC Sciences Products
  • >> More
Purity:
>98%
Synonyms:
10-Deacetyl-7-xylosyltaxol; 10-Deacetylpaclitaxel 7-Xyloside; 10-Deacetyltaxol 7-Xyloside
MSDS:
Inquire
1.Augmentation of response to nab-paclitaxel by inhibition of insulin-like growth factor (IGF) signaling in preclinical pancreatic cancer models.
Awasthi N1,2, Scire E3, Monahan S1, Grojean M4, Zhang E1, Schwarz MA5,2, Schwarz RE1,6. Oncotarget. 2016 Apr 26. doi: 10.18632/oncotarget.9029. [Epub ahead of print]
Nab-paclitaxel has recently shown greater efficacy in pancreatic ductal adenocarcinoma (PDAC). Insulin like growth factor (IGF) signaling proteins are frequently overexpressed in PDAC and correlate with aggressive tumor phenotype and poor prognosis. We evaluated the improvement in nab-paclitaxel response by addition of BMS-754807, a small molecule inhibitor of IGF-1R/IR signaling, in preclinical PDAC models. In subcutaneous xenografts using AsPC-1 cells, average net tumor growth in different therapy groups was 248.3 mm3 in controls, 42.4 mm3 after nab-paclitaxel (p = 0.002), 93.3 mm3 after BMS-754807 (p = 0.01) and 1.9 mm3 after nab-paclitaxel plus BMS-754807 (p = 0.0002). In subcutaneous xenografts using Panc-1 cells, average net tumor growth in different therapy groups was: 294.3 mm3 in controls, 23.1 mm3 after nab-paclitaxel (p = 0.002), 118.2 mm3 after BMS-754807 (p = 0.02) and -87.4 mm3 (tumor regression) after nab-paclitaxel plus BMS-754807 (p = 0.
2.Outcomes of Patients With Surgically and Pathologically Staged IIIA-IVB Pure Endometrioid-type Endometrial Cancer: A Taiwanese Gynecology Oncology Group (TGOG-2005) Retrospective Cohort Study (A STROBE-Compliant Article).
Chen JR1, Chang TC, Fu HC, Lau HY, Chen IH, Ke YM, Liang YL, Chiang AJ, Huang CY, Chen YC, Hong MK, Wang YC, Huang KF, Hsiao SM, Wang PH. Medicine (Baltimore). 2016 Apr;95(15):e3330. doi: 10.1097/MD.0000000000003330.
In the management of patients with advanced-stage pure endometrioid-type endometrial cancer (E-EC), such as positive lymph nodes (stage III) or stage IV, treatment options are severely limited. This article aims to investigate the outcome of women with FIGO III-IV E-EC (based on FIGO 2009 system).The retrospective cohort study, based on the Taiwanese Gynecologic Oncology Group (TGOG-2005), enrolled patients undergoing staging surgery to have a pathologically confirmed FIGO III-IV E-EC from 22-member hospitals between 1991 and 2010.This cohort included 541 patients (stage III, n = 464; stage IV, n = 77). Five-year overall survival (OS) was 70.4%. Median progression-free survival (PFS) was 43 months (range 0-258 months) and median OS was 52 months (range 1-258 months). Multivariate analysis showed that FIGO stage, >1/2 myometrial invasion (hazard ratio [HR] 1.53, 95% confidence interval [CI] 1.12-2.09; P = 0.007), histological grade 3 (HR 2.
3.Modified chitosan thermosensitive hydrogel enables sustained and efficient anti-tumor therapy via intratumoral injection.
Jiang Y1, Meng X1, Wu Z2, Qi X3. Carbohydr Polym. 2016 Jun 25;144:245-53. doi: 10.1016/j.carbpol.2016.02.059. Epub 2016 Feb 23.
Thermosensitive in situ hydrogels are potential candidates to achieve intratumoral administration, nevertheless their weak mechanical strength always lead to serious drug leakage and burst. Herein, we developed a chitosan based thermosensitive hydrogel of high mechanical strength, which was modified by glutaraldehyde (GA) and polyvinyl alcohol (PVA), for intratumoral delivery of paclitaxel (PTX). The modified hydrogel system could achieve sol-gel transition at 35.79±0.4°C and exhibit a 7.03-fold greater mechanical strength compared with simple chitosan hydrogel. Moreover, the drug release of PTX loaded modified hydrogel in PBS (pH 7.4) was found to be extended to 13 days. After intratumoral administration in mice bearing H22 tumors, PTX-loaded modified hydrogels exhibited a 3.72-fold greater antitumor activity compared with Taxol(®). Overall, these modified hydrogel systems demonstrated to be a promising way to achieve efficient sustained release and enhanced anti-tumor therapy efficiency of anticancer drugs through in situ tumor injectable administration.
4.Up-regulation of KIF14 is a predictor of poor survival and a novel prognostic biomarker of chemoresistance to paclitaxel treatment in cervical cancer.
Wang W1, Shi Y1, Li J2, Cui W2, Yang B3. Biosci Rep. 2016 Apr 5;36(2). pii: e00315. Print 2016 Apr.
Kinesin family member 14 (KIF14) is a member of kinesin family proteins which have been found to be dysregulated in various cancer types. However, the expression of KIF14 and its potential prognostic significance have not been investigated in cervical cancer. Real-time PCR was performed to assess the expression levels of KIF14 in 47 pairs of cervical cancer tissues and their matched normal tissues from patients who had not been exposed to chemotherapy as well as tissue samples from 57 cervical cancer patients who are sensitive to paclitaxel treatment and 53 patients who are resistant. The association between KIF14 expression levels in tissue and clinicopathological features or chemosensitivity was examined. Kaplan-Meier analysis and Cox proportional hazards model were applied to assess the correlation between KIF14 expression levels and overall survival (OS) of cervical cancer patients. KIF14 expression levels were significantly increased in cervical cancer tissues compared with matched non-cancerous tissues and it was higher in tissues of patients who are chemoresistant compared with those who are chemosensitive.
Molecular Weight Calculator Molarity Calculator Solution Dilution Calculator

Related ADCs Cytotoxin Products


CAS 25316-40-9 Doxorubicin hydrochloride

Doxorubicin hydrochloride
(CAS: 25316-40-9)

Doxorubicin (Adriamycin) is an antibiotic agent that inhibits DNA topoisomerase II and induces DNA damage and apoptosis. It is a drug used in cancer chemotherap...

CAS 66547-09-9 Ansamitocin P-3

Ansamitocin P-3
(CAS: 66547-09-9)

Ansamitocin P-3, a potent anti-tumor maytansinoid found in Actinosynnema pretiosum, is a maytansine analog which displays potent cytotoxicity against the human ...

CAS 90332-63-1 10-Deacetyl-7-xylosyl paclitaxel

10-Deacetyl-7-xylosyl paclitaxel
(CAS: 90332-63-1)

10-Deacetyl-7-xylosyl paclitaxel is a Paclitaxel derivative with improved pharmacological features and higher water solubility. It induced mitotic cell cycle ar...

CAS 474645-27-7 MMAE

MMAE
(CAS: 474645-27-7)

MMAE, whose full name is Monomethyl auristatin E, inhibits tubulin polymerization so that it inhibits cell division.

CAS 59-05-2 Methotrexate

Methotrexate
(CAS: 59-05-2)

Methotrexate, a folate antagonist, is a potent anti-inflammatory agent when used weekly in low concentrations, the anti-phlogistic action of which is due to inc...

Aldoxorubicin hydrochloride
(CAS: 480998-12-7)

Aldoxorubicin is the 6-maleimidocaproyl hydrazone derivative prodrug of the anthracycline antibiotic doxorubicin (DOXO-EMCH) with antineoplastic activity.

CAS 173441-26-4 MMAD hydrochloride

MMAD hydrochloride
(CAS: 173441-26-4)

For comparison purposes, the ADC A1 -mc-MMAD and/or A1 -vc-MMAD were used. The linker payload, mc-MMAD (6-maleimidocaproyl-monomethylauristatin-D) was conjugate...

CAS 110417-88-4 Dolastatin 10

Dolastatin 10
(CAS: 110417-88-4)

Dolastatin 10 is an inhibitior of microtubule disassembly (IC50= 1.2μM) and potently inhibits vincristine binding to tubulin in a noncompetitive manner ( Ki= 1....

CAS 38748-32-2 Triptolide

Triptolide
(CAS: 38748-32-2)

Triptolide is a diterpenoid epoxide found in the Thunder God Vine, Tripterygium wilfordii, which has been used in traditional Chinese medicine for more than two...

CAS 20830-81-3 Daunorubicin

Daunorubicin
(CAS: 20830-81-3)

Daunorubicin hydrochloride is the hydrochloride salt of an anthracycline antineoplastic antibiotic with therapeutic effects similar to those of doxorubicin. Dau...

CAS 57103-68-1 Maytansinol

Maytansinol
(CAS: 57103-68-1)

Maytansinol disrupts the mitotic spindle and prevents mitotic exit in Drosophila used in the preparation of site-specific trastuzumab maytansinoid antibody-drug...

CAS 108212-75-5 Calicheamicin

Calicheamicin
(CAS: 108212-75-5)

Calicheamicin, also known as Calichemicin γ1, is an potent enediyne antitumor antibiotics derived from the bacterium Micromonospora echinospora. Calicheamicin t...

CAS 1415246-68-2 MMAF Hydrochloride

MMAF Hydrochloride
(CAS: 1415246-68-2)

MMAF is a new auristatin derivative with a charged C-terminal phenylalanine that attenuates its cytotoxic activity compared to its uncharged counterpart, Monome...

CAS 160800-57-7 Auristatin E

Auristatin E
(CAS: 160800-57-7)

Auristatin E is a cytotoxic tubulin modifier with potent and selective antitumor activity; MMAE analog and cytotoxin in Antibody-drug conjugates.

CAS 290304-24-4 Daun02

Daun02
(CAS: 290304-24-4)

Daunomycin is an important anti-tumor agent, mainly used in the treatment of acute leukemias. Daunomycin can inhibit DNA synthesis by the way of binding to DNA(...

CAS 745017-94-1 MMAF

MMAF
(CAS: 745017-94-1)

MMAF is an antitubulin agent that inhibit cell division by blocking the polymerization of tubulin and it has lower cytotoxic activity than MMAE. It is an antibo...

CAS 228266-41-9 Taltobulin trifluoroacetate

Taltobulin trifluoroacetate
(CAS: 228266-41-9)

HTI-286 significantly inhibited proliferation of all three hepatic tumor cell lines (mean IC50 = 2 nmol/L +/- 1 nmol/L) in vitro. Interestingly, no decrease in ...

CAS 23109-05-9 alpha-Amanitin

alpha-Amanitin
(CAS: 23109-05-9)

alpha-Amanitin, the major toxic bicyclic octapeptide of the mushroom Amanita phalloides, inhibits RNA polymerase II at 1 µg/ml, RNA polymerase III at 10 µg/ml a...

CAS 23541-50-6 Daunorubicin hydrochloride

Daunorubicin hydrochloride
(CAS: 23541-50-6)

Daunorubicin HCl inhibits both DNA and RNA synthesis and inhibits DNA synthesis with Ki of 0.02 μM. It is chemotherapeutic of the anthracycline family that is g...

CAS 33069-62-4 Taxol

Taxol
(CAS: 33069-62-4)

Taxol, also called Paclitaxel, derived from the bark of the Pacific yew tree, has a broad antineoplastic spectrum uused in cancer chemotherapy.It promotes and s...

Chemical Structure

CAS 90332-63-1 10-Deacetyl-7-xylosyl paclitaxel

Quick Inquiry

Verification code

Featured Items